TY 2021 GeneralExplanationAttachment
Name:
BRISTOL-MYERS SQUIBB PATIENT ASSISTANCE
| Identifier |
Return Reference |
Explanation |
| SUMMARY OF DIRECT CHARITABLE ACTIVITIES |
PART IX-A, LINE 1 |
THE BRISTOL-MYERS SQUIBB PATIENT ASSISTANCE FOUNDATION, INC. IS A 501(C)(3) NON-PROFIT ORGANIZATION THAT PROVIDES TEMPORARY ASSISTANCE IN THE FORM OF FREE MEDICATION TO ELIGIBLE PATIENTS WHO HAVE A FINANCIAL HARDSHIP, GENERALLY HAVE NO PUBLIC OR PRIVATE PRESCRIPTION DRUG INSURANCE, AND RESIDE WITHIN THE 50 STATES, PUERTO RICO AND THE US VIRGIN ISLANDS. THE FOUNDATION PROVIDES DRUG ASSISTANCE PROGRAMS TO QUALIFYING PATIENTS WITHOUT CHARGE AND ON A NON-DISCRIMINATORY BASIS FOR THE CARE OF QUALIFIED ILL AND NEEDY PATIENTS WHO WOULD OTHERWISE BE UNABLE TO PURCHASE PRESCRIPTION DRUGS.DIRECT PATIENT PROGRAMS THE FOUNDATION PROVIDES ASSISTANCE PROGRAMS DIRECTLY TO QUALIFYING PATIENTS WHO WOULD OTHERWISE BE UNABLE TO PURCHASE PRESCRIPTION DRUGS. PRODUCTS INCLUDE COUMADIN, DROXIA, ELIQUIS, EMPLICITI, NULOJIX, ONUREG, OPDIVO, ORENCIA, PRAVACHOL, SPRYCEL, YERVOY AND ZEPOSIA . THE FOUNDATION REVIEWS AND EVALUATES PATIENT APPLICATIONS FOR DISTRIBUTION OF PRESCRIPTION PHARMACEUTICAL PRODUCTS TO ELIGIBLE PATIENTS, AND ADMINISTERS THE DIRECT PATIENT PROGRAMS THROUGH LASH GROUP (A THIRD-PARTY CONTRACTOR). OVER 100,000 PATIENTS RECEIVED ASSISTANCE THROUGH DIRECT PATIENT PROGRAMS IN 2021. TOTAL: $1,770,871,242 |